Keyi Yang

Mr. Keyi Yang

German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
Keyi YangKeyi Yang
Keyi Yang
ZZZhi Zeng
Zhi Zeng
HPHu Peng
Hu Peng
YJYu Jiang
Yu Jiang
Purpose: Artificial intelligence (AI) plays a substantial role in many domains, including medical fields. However, we still lack evidence to support whether or not cancer patients will accept the clinical use of AI. This research aims to assess the attitudes of Chinese cancer patients toward the clinical use of artificial intelligence in medicine (AIM), and to analyze the possible influencing factors. Patients and methods: A questionnaire was delivered to 527 participants. Targeted people were Chinese cancer patients who were informed of their cancer diagnosis. Results: The effective response rate was 76.3% (402/527). Most cancer patients trusted AIMs in both stages of diagnosis and treatment, and participants who had heard of AIMs were more likely to trust them in the diagnosis phase. When an AIM’s diagnosis diverged from a human doctor’ s, ethnic minorities, and those who had received traditional Chinese medicine (TCM), had never received chemotherapy, were more likely to choose “AIM”, and when an AIM’s therapeutic advice diverged from a human doctor’s, male participants, and those who had received TCM or surgery, were more likely to choose “AIM”. Conclusion: Most Chinese cancer patients believed in the AIM to some extent. Nevertheless, most still thought that oncology physicians were more trustworthy when their opinions diverged. Participants’ gender, race, treatment received, and AIM related knowledge might influence their attitudes toward the AIM. Most participants thought AIM would assist oncology physicians in the future, while little really believed that oncology physicians would completely be replaced.

23 November 2023 in Cancer
Verified
Journal Article
Open access
Keyi YangKeyi Yang
Keyi Yang
DDDaniela Doege
Daniela Doege
MTMelissa S. Y. Thong
Melissa S. Y. Thong
LKLena Koch‐Gallenkamp
Lena Koch‐Gallenkamp
LWLinda Weisser
Linda Weisser
VAVolker Arndt
Volker Arndt
Background: Patients with cancer are at increased risk of diabetes mellitus (DM). Previous studies on the prevalence and prognostic impact of DM in cancer survivors were limited by small sample sizes or short follow‐up times. We aimed to compare the patient‐reported prevalence of DM in long‐term cancer survivors (LTCS), who survived 5 years or more after cancer diagnosis, with that in cancer‐free controls, and to estimate the mortality risk among LTCS according to DM status.Methods: Our population‐based cohort comprised 6952 LTCS diagnosed with breast, colorectal, or prostate cancer between 1994 and 2004, recruited in 2008–2011 (baseline), and followed until 2019. A total of 1828 cancer‐free individuals served as controls. Multivariable logistic regression was used to compare the prevalence of DM in LTCS and controls, and according to covariates at baseline. Mortality among LTCS according to DM was assessed by Cox proportional hazards regression.Results: A total of 962 (13.8%) LTCS at baseline reported DM. Prevalence of DM in LTCS was not higher than in cancer‐free controls, both at baseline (odds ratio, 0.80; 95% CI, 0.66–0.97) and at follow‐up (odds ratio, 0.83; 95% CI, 0.67–1.04). Prevalence of DM in LTCS was associated with cancer site, older age, lower education, higher socioeconomic deprivation, higher body mass index, physical inactivity, other comorbidities, and poorer prognosis (adjusted hazard ratio [all‐cause mortality] = 1.29; 95% CI, 1.15–1.44).Conclusion: DM in LTCS is prevalent, but not higher than in cancer‐free population controls. Cancer survivors with concurrent DM are at a potentially higher risk of death.Plain Language Summary: Cancer and diabetes mellitus (DM) are two serious threats to global health. In our study, prevalence of DM in long‐term cancer survivors who survived 5 years or more after cancer diagnosis was not higher than in cancer‐free controls. This should not be interpreted as an indication of a lower risk of DM in cancer survivors. Rather, it highlights the potentially poor prognosis in diabetic cancer survivors. Therefore, keeping a continuous satisfactory DM and hyperglycemia management is essential during long‐term cancer survivorship.

26 February 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
MBMaya Basbous
Maya Basbous
Keyi YangKeyi Yang
Keyi Yang
VAVolker Arndt
Volker Arndt
MTMelissa Thong
Melissa Thong
Prostate cancer accounts for the largest group of cancer survivors in men. Hormone therapy is essential, especially in advanced disease. While its short-term effects are well studied, research into the long-term effects on health-related quality of life (HRQOL) remains limited. Therefore, this review aims to synthesize and identify key gaps in the literature on HRQOL and symptom burden in long-term prostate cancer survivors who underwent hormone therapy. After searching four databases until 15 April 2025, we identified 14 observational studies that reported on general and prostate cancer-specific HRQOL in prostate cancer survivors ≥ 5 years post-diagnosis. Survivors who underwent hormone therapy reported worse global health status and physical, emotional, and social functioning compared to those treated with local therapies like prostatectomy or radiation. These survivors also experienced greater symptom burdens, alongside worse vitality and mental health. Prostate cancer-specific issues, such as bowel and urinary bother and sexual dysfunction, were also more pronounced in hormone therapy recipients. Nevertheless, outcomes beyond 15 years remain under-researched. The findings of this review highlight the importance of discussing long-term HRQOL compromises with patients who consider hormone therapy. However, they warrant cautious interpretation, particularly due to limited details on hormone therapy regimens and inadequate control for stage.